Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations?

Leukemia Research

Volumn 21, Issue 3, 1997, Pages 183-188

  Mehta, Jayesh ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Amphotericin B colloid dispersion; Amphotericin B lipid complex; Antifungal therapy; Fungal infections; Liposomal amphotericin; Nephrotoxicity

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; LIPOSOME;

CHEMICAL STRUCTURE; CHILL; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG STRUCTURE; FEVER; HUMAN; LIVER TOXICITY; MYCOSIS; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; VOMITING;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CHOLESTEROL ESTERS; DRUG COMBINATIONS; HUMANS; MOLECULAR STRUCTURE; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0030987958     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(96)00075-6     Document Type: Review

References (33)

1. Bodey G., Bueltmann B., Duguid W., Gibbs D., Hanak H., Hotchi M., Mall G., Martino P., Meunier F., Milliken S., Naoe S., Okudaira M., Sceuola D. & van't Wout J. (1992) Fungal infections in cancer patients: an international autopsy survey. Eur. J. Clin. Microbiol. Infect. Dis. 11, 99.
2. Burchard K. W., Lloyd M. D. & Minor L. B. (1983) Fungal sepsis in surgical patients. Arch. Surg. 118, 217.
3. Butler K. M. & Baker C. J. (1988) Candida: an increasingly important pathogen in the nursery. Pediatr. Clin. North Am. 35, 543.
4. Komshian S. V., Uwaydah A. K., Sohel J. D. & Crane L. R. (1989) Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev. Infect. Dis. 11, 379.
5. Sobel J. D. (1988) Candida infections in the intensive care unit. Crit. Care Clin. 4, 325.
6. Bowler W. A. & Oldfield E. C. (1992) New approaches to amphotericin B administration. Infect. Med. 9, 17.
7. Carr M. & Dismukes W. E. (1992) Antifungal drugs. In Infections Diseases (Gorbach J. L., Bartlett J. G. & Blacklow N. R., Eds), pp. 306-313. W. B. Saunders Company, Philadelphia.
8. Pizzo P. A., Meyers J., Freifeld A. G. & Walsh T. (1993) Infections in the cancer patient. In Cancer: Principles and Practice of Oncology (De Vita V. T., Hellman S. & Rosenberg S. A., Eds), pp. 2292-2333. J. B. Lippincott, Philadelphia.
9. Janoff A. S., Perkins W. R., Saleton S. L. & Swenson C. E. (1993) Amphotericin B lipid complex (ABLC): a molecular rationale for the attenuation of amphotericin B related toxicities. J. Liposome Res. 3, 451.
10. Lopez-Berenstein G., Melita R., Hopfer R., Mehta K., Hersh E. M. & Juliano R. (1983) Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis. Cancer Drug Del. 1, 37.
11. Szoka F. C. & Tang M. (1993) Amphotericin B formulated in liposomes and lipid based systems: a review. J. Liposome Res. 3, 363.
12. Guo L. S. S., Fielding R. M. & Lasic D. D. (1991) Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate discs. Intl J. Pharm. 75, 45.
13. Adler-Moore J. P. & Proftitt R. T. (1993) Development, characterization, efficacy and mode of action of AmBi-some, a unilamellar liposomal formulation of amphotericin B. J. Liposome Res. 3, 429.
14. Fielding R. M., Smith P. C., Wang L. H., Porter J. & Guo L. S. S. (1991) Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob. Agents Chemother. 35, 1208.
15. Proffitt R. T., Satorius A., Chiang S. M., Sullivan L. & Adler-Moor J. P. (1991) Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J. Antimicrob. Chemother. 28, Suppl B, 49.
16. Fielding R. M., Singer A. W., Wang L. H., Babbar S. & Guo L. S. S. (1992) Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob. Agents Chemother. 36, 299.
17. Taylor R. L., Williams D. M., Craven P. C., Graybill J. R., Drute D. J. & Magee W. E. (1982) Amphotericin B in liposomes: a novel therapy for histoplasmosis. Am. Rev. Resp. Dis. 125, 610.
18. Anaissie E. L., White M., Uzun O., Singer O., Bodey G. P., Azarnia N., Lopez-Berestein G. & Matzke D. (1995) Amphotericin B lipid complex (ABLC) vs amphotericin B (AMB) for treatment of hematogenous and invasive candidiasis: a prospective, randomized, multicenter trial. Proc. 35th Intersci. Conf. Antimicrob. Agents Chemother., April 1995, San Francisco, p. 330 (Abstr. LM21).
19. Hiemenz J. W., Lister J., Anaissie E. J., White M. H., Dinubile M., Silber J., Horwith G. & Lee L. W. (1995) Emergency-use amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis: historical control comparison with amphotericin B (abstr.). Blood 86, Suppl. 1, 849a.
20. Walsh T. J., Hiemenz J. W., Seffiel N. & Anaissie E. J. (1994) Amphotericin B lipid complex in the treatment of 228 cases of invasive mycosis. Proc. 34th Intersci. Conf. Antimicrob. Agents Chemother., October 1994, Orlando, p. 247 (Abstr. M69).
21. Mehta J., Kelsey S. M., Chu R., Powles R., Singhal S., Hazel D., Newland A. C. & Treleaven J. (1995) Amphotericin B lipid complex (ABLC) for fungal sepsis in immunocompromised patients (abstr.). Blood 86, Suppl 1, 513a.
22. Cannon R., Mamelok R., Pietrelli L. & Dumond C. (1994) Renal sparing of amphotericin B colloidal dispersion (ABCD; Amphocil). Proc. 34th Intersci. Conf. Antimicrob. Agents Chemother., October 1994, Orlando, Abstr. 103.
23. Tollemar J. & Ringdén O. (1995) Lipid formulations of amphotericin B - less toxicity but at what economic cost? Drug Safety 13, 207.
24. Bowden R. A. & Cays M. (1993) Phase I safety study of amphotericin B colloidal dispersion (ABCD: amphocil) for the treatment of invasive fungal infection after marrow transplant (abstr.). Blood 82, Suppl 1, 425a.
25. Ringdén O., Meunier F., Tollemar J., Ricci R., Tura S., Kuse E., Viviani M. A., Gorin N. C., Klastersky J. & Fénaux P. (1991) Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J. Antimicrob. Chemother. 28, Suppl B, 73.
26. Coker R. L. Jr, Viviani M., Gazzard B. G., Du Pont B., Polile H. D., Murphy S. M., Atouguia J., Champalimaud J. L. & Harris J. R. (1993) Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 7, 829.
27. Tollemar J., Ringdén O., Andersson S., Sundberg P., Ljungman P., Sparrelid E. & Tydén G. (1993) Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections: a randomized trial in bone marrow transplant recipients. Transpl. Proc. 25, 1495.
28. Mills W., Chopra R., Linch D. C. & Goldstone A. H. (1994) Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br. J. Haematol. 86, 754.
29. Herbrecht R. (1993) Safety of amphotericin B colloidal dispersion (ABCD) in disseminated fungal infections. In Amphotericin B Colloidal Dispersion (ABCD) in the Treatment of Disseminated fungal infections. Proc. Round Table Semin., 30 Sept 1993 (Mackenzie D. W. R., Ed.), pp. 49-56. Royal Society of Medicine Services Ltd, London.
30. Goulding N. M. (1994) Drug alert (letter). MDR 22-12194. Medicines Control Agency, London.
31. Meunier F., Prentice H. G. & Ringdén O. (1991) Liposomal, amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J. Antimicrob. Chemother. 28, Suppl B, 83.
32. Walsh T. J. & Pizzo A. (1988) Treatment of systemic fungal infections: recent progress and current problems. Eur. J. Clin. Microbiol. Infect. Dis. 7, 460.
33. Meunier F. (1994) Management of candidemia. N. Engl. J. Med. 331, 1371.